We’re experiencing issues for some mobile devices with our ARTG dataset filter function. We apologise for any inconvenience while we work to fix this.
ENHERTU AstraZeneca Pty Ltd
Product name
ENHERTU
Sponsor
Accepted date
Jan-2026
Active ingredients
trastuzumab deruxtecan
Summary of proposed indication
ENHERTU followed by THP (a taxane, trastuzumab, and pertuzumab) is indicated for the neoadjuvant treatment of adult patients with HER2-positive Stage II or III breast cancer’
Application type
C (new indication)
Publication date
Jan-2026